Switzerland· 61636002
Cinryze 500 IE, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
A c1-inhibitor, plasma derived product containing c1-esterasi inhibitor humanus, registered in Switzerland by Takeda Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
C1-inhibitor, plasma derived is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
C1-inhibitor, plasma derived · ATC B06AC01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- C1-esterasi inhibitor humanus
- Manufacturer
- Takeda Pharma AG
- Country
- Switzerland (CH)
- ATC code
- B06AC01
- ATC class
- C1-inhibitor, plasma derived
- Defined daily dose
- 1.4 TSD, E
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680616360021Durchstf 2 StkCHF 1337.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
47 interactions on record for c1-inhibitor, plasma derived.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
C1-inhibitor, plasma derived · interactions on record
47 records
- 5 severe
- 42 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B06AC01
C1-inhibitor, plasma derived, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9f8abc6-c9ee-473c-a33b-74a404d7fbb7 GET /v1/drugs/e9f8abc6-c9ee-473c-a33b-74a404d7fbb7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "c1-esterasi inhibitor humanus 500 UI",
"valid_from": "2025-03-01",
"limitations": "[{\"description\":\"Hereditäres Angioödem infolge C1-Inhibitor-Mangel: Behandlung und präoperative Prävention von Attacken. Langzeit Prophylaxe alle 3 oder 4 Tage bei Patienten mit mindestens 2 Attacken pro Monat, bei denen eine Therapie mit Androgenen oder Tranexamsäure keinen ausreichenden Erfolg brachte oder mit unzumutbaren Nebenwirkungen verbunden ist.<br>\\nVor Erstverschreibung der Langzeit-Prophylaxe ist eine Kostengutsprache durch den Krankenversicherer nach Rücksprache mit dem Vertrauensarzt erforderlich.<br>\\nDie Erstverschreibung der Langzeit-Prophylaxe darf nur von den Universitätszentren, den Kantonsspitälern Aarau, Bellinzona, Chur, Luzern, Sitten/Sion oder St. Gallen oder einem mit diesen Zentren kooperierenden niedergelassenen Arzt erfolgen, um eine patientennahe Versorgung zu gewährleisten. Die Kooperation geschieht auf einvernehmlicher Basis zwischen beiden Partnern.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2020-06-01\",\"validTo\":null}]",
"galenic_form": "Trockensub 500 E c Solv",
"therapeutic_area": null,
"sl_inclusion_date": "2014-10-01",
"self_retention_pct": 10
}See everything about c1-inhibitor, plasma derived.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.